Heidelberg, June 11, 2024

Precisis has introduced EASEE® to Portugal in collaboration with Pagaimo Medical

Heidelberg, 11.06.2024 – Precisis GmbH, a leading company in medical technology, has introduced EASEE®, a groundbreaking brain pacemaker for drug-resistant epilepsies, in Portugal in partnership with Pagaimo Medical.

In Portugal, over 60,000 people suffer from focal epilepsies, with approximately 30% being drug-resistant. This advanced system uses high-frequency and direct-current-like pulses to regulate brain activity and reduce seizures. EASEE® thus offers a crucial innovative treatment option for individuals with drug-resistant focal epilepsies.

Clinical results show a responder rate of 53% after 6 months of stimulation, which improves with prolonged use. EASEE® is available to epilepsy patients aged 18 and over with drug-resistant focal epilepsies, expanding their treatment options.

Precisis is excited to collaborate with Pagaimo Medical, renowned neurostimulation experts in Portugal, to jointly enhance the availability of EASEE® nationwide.

The development of neurostimulation devices to improve the quality of life for people with functional brain disorders is the focus of Precisis GmbH, based in Heidelberg. The introduction of EASEE® in Portugal represents a significant advancement in this mission.


Further Information

Precisis GmbH
Margot-Becke-Ring 8
69124 Heidelberg

Phone +49 6221 6559300
Fax +49 6221 6559310


Precisis GmbH
Alisa Öhrström, MSc.

We use cookies and other technologies on our website. Some of them are essential, while others help us to improve this website and your experience with it. For more information about how we use your data, please see our Privacy Policy.